Harrow Inc. (HROW)
NASDAQ: HROWHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
HROW stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.14B
- Forward P/E
- 16.26
- EPS (TTM)
- -$0.76
- Dividend yield
- None
- 52-week range
- 25.76 – 54.85
- Day range
- 30.32 – 32.43
- Volume / Avg
- 911.03K / 626.20K
- Beta
- —
- Shares outstanding
- 37.53M
52-week range
HROW stock today
Shares of Harrow (HROW) finished lower on Nov 20 at $30.41, a drop of 5.35% or $1.72 per share, versus the S&P 500's 3.70% decline. At this level, HROW sits near the bottom of its 52-week range of $25.76 to $54.85: 44.6% below the high, set on Jan 7, 2026 and 18.1% above the low. HROW is down 37.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 21.8%.
Harrow has posted a net loss over the last twelve months (EPS of -$0.76), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Harrow
Company profileHarrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Mark L. Baum J.D.
- Headquarters
- Nashville, TN
- Employees
- 373
- Website
- harrow.com
Financial highlights
Full financialsIn fiscal 2025, Harrow generated $272.3 million in revenue, up 36.4% from fiscal 2024, its 5th consecutive year of revenue growth. Harrow reported a net loss of $5.1 million, compared with a loss of $17.5 million a year earlier. Gross margin was 75.1% (down from 75.3%) and operating margin 11.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $272.30M | $199.61M | $130.19M | $88.59M | $72.48M |
| Growth | +36.41% | +53.32% | +46.95% | +22.24% | +48.30% |
| Net income | $-5.14M | $-17.48M | $-24.41M | $-14.09M | $-18.01M |
| EPS (diluted) | $-0.14 | $-0.49 | $-0.75 | $-0.51 | $-0.69 |
Analyst forecast
ForecastConsensus (9 analysts)
strong_buy
Avg. price target
$62.25+104.70%
- Strong buy 0
- Buy 9
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $0.25 vs $0.13
- Surprise
- +92.31%
HROW news
All HROW newsHarrow peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CMPSCOMPASS Pathways Plc American Depository Shares | 8.05 | -6.94% | $1.14B | vs HROW |
| GPCRStructure Therapeutics Inc. ADR | 16.13 | -5.78% | $1.15B | vs HROW |
| AAPGAscentage Pharma Group International American Depository Shares | 11.97 | -3.78% | $1.12B | vs HROW |
| OPKOPKO Health Inc. | 1.57 | -2.48% | $1.17B | vs HROW |
| KARDKardigan Inc. | 11.54 | -7.83% | $1.08B | vs HROW |
| GHRSGH Research PLC | 17.53 | -5.55% | $1.20B | vs HROW |
| AMPHAmphastar Pharmaceuticals Inc. | 28.25 | +0.50% | $1.20B | vs HROW |
| MLYSMineralys Therapeutics Inc. | 13.66 | -3.53% | $1.21B | vs HROW |
Indexes, lists and sector
Harrow stock FAQ
What is Harrow's stock price today?
HROW last traded at $30.41 as of Nov 20, 4:00 PM EST, down 5.35% on the day. Prices are delayed at least 15 minutes.
Does Harrow pay a dividend?
No. Harrow does not currently pay a regular cash dividend.
Who is Harrow's CEO?
Mr. Mark L. Baum J.D. is the chief executive officer of Harrow Inc., which has about 373 employees.
Has HROW ever split its stock?
Yes. The most recent HROW stock split was a 1-for-5 split on Feb 8, 2013, one of 2 splits on record.
What is the HROW 52-week high?
The 52-week high for HROW is $54.85 and the 52-week low is $25.76. The stock is currently 44.6% below its high.